Cannabis-based Extracts And Topical Formulations For Use In Skin Disorders
The present invention discloses a pharmaceutical topical composition comprising cannabidiol (CBD) or a derivative thereof and Tetrahydrocannabinol (THC) or a derivative thereof in an about 1:1 ratio, useful for treatment or prevention of inflammatory skin disorders, and treatment methods thereof.
Claim CLM-00001. 1. A method of treating or inhibiting an inflammatory skin disease in a human in need thereof comprising topically administering to the human a therapeutically effective amount of a pharmaceutical composition comprising:
a. a carrier formulation comprising β-caryophyllene, salicylic acid, and at least at least one of:
i. glycerin; orii. niacinamide; and
b. cannabis oil comprising cannabidiol and tetrahydrocannabinol, wherein the inflammatory skin disease is selected from the group consisting of spongiotic dermatitides, psoriasiform dermatitides, interface dermatitides, bullous disease, dermatitides with perivascular inflammation, vasculitis, nodular and diffuse dermatitides, seborrheic dermatitis, lupus erythematosus, discoid lupus erythematosus, dermatomyositis, lichen planus, lichen sclerosus, lichen simplex chronicus, psoriasis, lichen striatus, lichen aureus, granuloma faciale, atopic dermatitis, sweet syndrome, granuloma inguinale, pyoderma gangrenosum, necrobiotic xanthogranuloma, pemphigus, pemphigus foliaceus, pemphigus vulgaris, dermatitis herpetiformis, erythema multiforme, follicular occlusion triad, ruptured cyst/follicle, cutaneous T-cells lymphoma, poison ivy, nummular dermatitis, and eczema.
